Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Mutation Causing Lesch-Nyhan Syndrome Linked to Other Neurological Disorders

By BiotechDaily International staff writers
Posted on 21 Oct 2013
Scientists have shown that gene expression errors impair the ability of stem cells to produce normal neurons, resulting instead in neurological disease. They indicate that at least some distinctly different neurodevelopmental and neurodegenerative disorders share basic, causative defects.

A gene mutation that causes a rare but destructive neurological disorder known as Lesch-Nyhan syndrome could help explain the developmental and neuronal defects found in other, diverse neurological disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Lesch-Nyhan syndrome is caused by defects in the hypoxanthine guanine phosphoribosyltransferacgene (HPRT1), a gene that helps generate purine nucleotides, needed for DNA and RNA.

The findings, published in the October 9, 2013, issue of the journal PLOS ONE provide the first experimental picture of how gene expression errors impair the ability of stem cells to produce normal neurons, resulting instead in neurological disease. They indicate that at least some distinctly different neurodevelopmental and neurodegenerative disorders share basic, causative defects.

Mutations in the HPRT gene result in deficiencies in the HPRT enzyme, leading to defective expression of the neurotransmitter dopamine and subsequent abnormal neuron function. HPRT mutation is the specific cause of Lesch-Nyhan, an inherited neurodevelopmental disorder characterized by uncontrollable repetitive body movements, cognitive defects and compulsive self-mutilating behaviors.

They discovered that the cells do not develop normally. Instead, they differentiate from full-fledged neurons into cells that resemble and partially function as neurons, but also perform functions more typical of glial cells, a kind of supporting cell in the central nervous system. In addition, they noted that HPRT deficiency causes abnormal regulation of many cellular functions controlling important operational and reproduction mechanisms, DNA replication and repair and many metabolic processes.

The scientific team, headed by Theodore Friedmann, MD, professor of pediatrics at the University of California, San Diego School of Medicine (USA), says a gene mutation that causes a rare but destructive neurological disorder known as Lesch-Nyhan syndrome appears to explain the developmental and neuronal defects found in other, diverse neurological disorders like Alzheimer’s, Parkinson’s and Huntington’s diseases.

The scientists say that understanding defects in Lesch-Nyhan could help identify errant processes in other, more common neurological disorders, perhaps pointing the way to new kinds of therapies. Lesch-Nyhan syndrome is caused by defects in the hypoxanthine guanine phosphoribosyltransferacgene (HPRT1), a gene that is well-known for its essential tasks among them helping generate purine nucleotides–the building blocks of DNA and RNA.

“We believe that the neural aberrations of HPRT deficiency are the consequence of these combined, multisystem metabolic errors,” said Prof. Friedmann. “And since some of these aberrations are also found in other neurological disorders, we think they almost certainly play some role in causing the neurological abnormalities in diseases like Alzheimer’s, Parkinson’s, Huntington’s and possibly others. That makes them potential therapeutic targets for conditions that currently have limited or no treatments, let alone cures.”

Related Links:

University of California, San Diego School of Medicine



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.